阿片受体在肿瘤中的研究进展
Research Progress on Opioid Receptors in Malignant Tumors
DOI: 10.12677/acm.2026.162357, PDF,   
作者: 唐兴志:右江民族医学院研究生学院,广西 百色;吴 军*:右江民族医学院附属医院泌尿外科,广西 百色
关键词: 阿片受体肿瘤微环境肿瘤进展疼痛管理免疫调节靶向治疗Opioid Receptors Tumor Microenvironment Tumor Progression Pain Management Immune Regulation Targeted Therapy
摘要: 阿片受体作为G蛋白偶联受体家族的重要成员,不仅是阿片类药物镇痛作用的关键靶点,近年来其在肿瘤生物学中的复杂作用日益受到关注。本综述系统阐述了阿片受体在肿瘤发生、发展与转移中的研究进展,重点分析了其在肿瘤微环境中的表达与功能,包括对免疫细胞、肿瘤细胞自身及其他非细胞组分的调控作用。同时总结了阿片受体对肿瘤细胞增殖、凋亡、转移、血管生成等生物学行为所具有的双重调节效应,并探讨了长期使用阿片类药物对疼痛管理与肿瘤进展可能产生的复杂影响。此外,本综述还展望了靶向阿片受体在抗肿瘤治疗中的潜在价值,例如开发选择性激动剂/拮抗剂、与免疫治疗联合等策略,以期为开发兼顾有效镇痛与肿瘤控制的新型治疗策略提供理论依据。
Abstract: As pivotal members of the G protein-coupled receptor family, opioid receptors serve not only as key targets for opioid analgesia but have also garnered increasing attention in recent years for their complex roles in tumor biology. This review systematically outlines recent advances in the study of opioid receptors in tumor initiation, progression, and metastasis, with a focus on their expression and functions within the tumor microenvironment, including their regulatory effects on immune cells, tumor cells, and other non-cellular components. It also summarizes the dual regulatory effects of opioid receptors on tumor cell behaviors such as proliferation, apoptosis, metastasis, and angiogenesis, and discusses the complex implications of long-term opioid use for both pain management and tumor progression. Furthermore, this review explores the potential of targeting opioid receptors in anticancer therapy, proposing strategies such as developing selective agonists/antagonists and combining opioid receptor modulation with immunotherapy, with the aim of providing a theoretical foundation for novel therapeutic approaches that effectively balance analgesia and tumor control.
文章引用:唐兴志, 吴军. 阿片受体在肿瘤中的研究进展[J]. 临床医学进展, 2026, 16(2): 25-30. https://doi.org/10.12677/acm.2026.162357

参考文献

[1] Wang, R., Li, S., Wang, B. and Zheng, H. (2024) Impact of Opioids and Mu-Opioid Receptors on Oncologic Metastasis. American Journal of Cancer Research, 14, 4236-4247. [Google Scholar] [CrossRef] [PubMed]
[2] Bhoir, S., Uhelski, M., Guerra‐Londono, J.J. and Cata, J.P. (2023) The Role of Opioid Receptors in Cancer. Advanced Biology, 7, e2300102. [Google Scholar] [CrossRef] [PubMed]
[3] Cheng, H.S., Lee, J.X.T., Wahli, W. and Tan, N.S. (2019) Exploiting Vulnerabilities of Cancer by Targeting Nuclear Receptors of Stromal Cells in Tumor Microenvironment. Molecular Cancer, 18, Article No. 51. [Google Scholar] [CrossRef] [PubMed]
[4] Emami, F., Pathak, S., Nguyen, T.T., Shrestha, P., Maharjan, S., Kim, J.O., et al. (2021) Photoimmunotherapy with Cetuximab-Conjugated Gold Nanorods Reduces Drug Resistance in Triple Negative Breast Cancer Spheroids with Enhanced Infiltration of Tumor-Associated Macrophages. Journal of Controlled Release, 329, 645-664. [Google Scholar] [CrossRef] [PubMed]
[5] Wu, S., Chen, J., Huang, E. and Zhang, Y. (2023) Pan-Cancer Analysis and Validation of Opioid-Related Receptors Reveals the Immunotherapeutic Value of Toll-Like Receptor 4. International Journal of General Medicine, 16, 5527-5548. [Google Scholar] [CrossRef] [PubMed]
[6] Zheng, R. and Ma, J. (2022) Immunotherapeutic Implications of Toll-Like Receptors Activation in Tumor Microenvironment. Pharmaceutics, 14, Article 2285. [Google Scholar] [CrossRef] [PubMed]
[7] Bhardwaj, A., Prasad, D. and Mukherjee, S. (2023) Role of Toll-Like Receptor in the Pathogenesis of Oral Cancer. Cell Biochemistry and Biophysics, 82, 91-105. [Google Scholar] [CrossRef] [PubMed]
[8] Fichna, J. and Janecka, A. (2004) Opioid Peptides in Cancer. Cancer and Metastasis Reviews, 23, 351-366. [Google Scholar] [CrossRef] [PubMed]
[9] de Sousa, A., Dantas, T., Barros Silva, P., Martins, C., Freire, G., Junior, H., et al. (2021) Analysis of the Immunoexpression of Opioid Receptors and Their Correlation with Markers of Angiogenesis, Cell Proliferation and Apoptosis in Breast Cancer. Asian Pacific Journal of Cancer Prevention, 22, 633-640. [Google Scholar] [CrossRef] [PubMed]
[10] Jia, K., Sun, D., Ling, S., Tian, Y., Yang, X., Sui, J., et al. (2014) Activated δ-Opioid Receptors Inhibit Hydrogen Peroxide-Induced Apoptosis in Liver Cancer Cells through the PKC/ERK Signaling Pathway. Molecular Medicine Reports, 10, 839-847. [Google Scholar] [CrossRef] [PubMed]
[11] Justus, C.R., Dong, L. and Yang, L.V. (2013) Acidic Tumor Microenvironment and pH-Sensing G Protein-Coupled Receptors. Frontiers in Physiology, 4, Article 354. [Google Scholar] [CrossRef] [PubMed]
[12] Cambria, E., Coughlin, M.F., Floryan, M.A., Offeddu, G.S., Shelton, S.E. and Kamm, R.D. (2024) Linking Cell Mechanical Memory and Cancer Metastasis. Nature Reviews Cancer, 24, 216-228. [Google Scholar] [CrossRef] [PubMed]
[13] Kharmate, G., Rajput, P.S., Lin, Y. and Kumar, U. (2013) Inhibition of Tumor Promoting Signals by Activation of SSTR2 and Opioid Receptors in Human Breast Cancer Cells. Cancer Cell International, 13, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[14] Harper, P., Hald, O., Lwaleed, B.A., Kyyaly, A., Johnston, D., Cooper, A.J., et al. (2018) The Impact of Morphine Treatment on Bladder Cancer Cell Proliferation and Apoptosis: In Vitro Studies. Experimental Oncology, 40, 190-193. [Google Scholar] [CrossRef
[15] Paskeh, M.D.A., Ghadyani, F., Hashemi, M., Abbaspour, A., Zabolian, A., Javanshir, S., et al. (2023) Biological Impact and Therapeutic Perspective of Targeting PI3K/Akt Signaling in Hepatocellular Carcinoma: Promises and Challenges. Pharmacological Research, 187, Article ID: 106553. [Google Scholar] [CrossRef] [PubMed]
[16] Zhang, H., Zhou, D., Gu, J., Qu, M., Guo, K., Chen, W., et al. (2021) Targeting the Mu-Opioid Receptor for Cancer Treatment. Current Oncology Reports, 23, Article No. 111. [Google Scholar] [CrossRef] [PubMed]
[17] Guelfi, S., Hodivala-Dilke, K. and Bergers, G. (2024) Targeting the Tumour Vasculature: From Vessel Destruction to Promotion. Nature Reviews Cancer, 24, 655-675. [Google Scholar] [CrossRef] [PubMed]
[18] Seylani, A., Haile, Y. and Sadighian, A. (2025) Abstract B016: Beyond VEGF: Distinct Angiogenic Landscapes in ATM and BRCA1/2-Mutated Ovarian Tumors. Cancer Research, 85, B016. [Google Scholar] [CrossRef
[19] Santoni, A., Santoni, M. and Arcuri, E. (2022) Chronic Cancer Pain: Opioids within Tumor Microenvironment Affect Neuroinflammation, Tumor and Pain Evolution. Cancers, 14, Article 2253. [Google Scholar] [CrossRef] [PubMed]
[20] ALSalamat, H.A., Abuarab, S.F., Salamah, H.M., Ishqair, A.H., Dwikat, M.F., Nourelden, A.Z., et al. (2024) Cannabis and Cancer: Unveiling the Potential of a Green Ally in Breast, Colorectal, and Prostate Cancer. Journal of Cannabis Research, 6, Article No. 24. [Google Scholar] [CrossRef] [PubMed]
[21] Soleimani, A., Bahreyni, A., Roshan, M.K., Soltani, A., Ryzhikov, M., Shafiee, M., et al. (2018) Therapeutic Potency of Pharmacological Adenosine Receptors Agonist/antagonist on Cancer Cell Apoptosis in Tumor Microenvironment, Current Status, and Perspectives. Journal of Cellular Physiology, 234, 2329-2336. [Google Scholar] [CrossRef] [PubMed]
[22] Dai, Z., Wang, Z., Lei, K., Liao, J., Peng, Z., Lin, M., et al. (2025) Corrigendum to “Irreversible Electroporation Induces CD8+ T Cell Immune Response against Post-Ablation Hepatocellular Carcinoma Growth” [Cancer Lett. 503 (2021) 1-10.]. Cancer Letters, 633, Article ID: 217973. [Google Scholar] [CrossRef
[23] Jiao, R., Lin, X., Zhang, Q., Zhang, Y., Qin, W., Yang, Q., et al. (2024) Anti-Tumor Immune Potentiation Targets-Engineered Nanobiotechnologies: Design Principles and Applications. Progress in Materials Science, 142, Article ID: 101230. [Google Scholar] [CrossRef
[24] Gong, Y., Zhang, L., Liu, Y., Tang, M., Lin, J., Chen, X., et al. (2023) Neutrophils as Potential Therapeutic Targets for Breast Cancer. Pharmacological Research, 198, Article ID: 106996. [Google Scholar] [CrossRef] [PubMed]
[25] Faupel-Badger, J., Kohaar, I., Bahl, M., Chan, A.T., Campbell, J.D., Ding, L., et al. (2024) Defining Precancer: A Grand Challenge for the Cancer Community. Nature Reviews Cancer, 24, 792-809. [Google Scholar] [CrossRef] [PubMed]